These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19936977)

  • 41. Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology.
    Boot E; Booij J; Abeling N; Meijer J; da Silva Alves F; Zinkstok J; Baas F; Linszen D; van Amelsvoort T
    J Psychopharmacol; 2011 Jul; 25(7):888-95. PubMed ID: 21447540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.
    Tiwari AK; Deshpande SN; Lerer B; Nimgaonkar VL; Thelma BK
    Pharmacogenomics J; 2007 Oct; 7(5):305-11. PubMed ID: 16969362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.
    Gutiérrez B; Arranz MJ; Huezo-Diaz P; Dempster D; Matthiasson P; Travis M; Munro J; Osborne S; Kerwin RW
    Schizophr Res; 2002 Nov; 58(1):93-7. PubMed ID: 12363396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Schizophrenia as a GSK-3 dysregulation disorder.
    Lovestone S; Killick R; Di Forti M; Murray R
    Trends Neurosci; 2007 Apr; 30(4):142-9. PubMed ID: 17324475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
    J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease.
    Kwok JB; Hallupp M; Loy CT; Chan DK; Woo J; Mellick GD; Buchanan DD; Silburn PA; Halliday GM; Schofield PR
    Ann Neurol; 2005 Dec; 58(6):829-39. PubMed ID: 16315267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia.
    Ide M; Ohnishi T; Murayama M; Matsumoto I; Yamada K; Iwayama Y; Dedova I; Toyota T; Asada T; Takashima A; Yoshikawa T
    J Neurochem; 2006 Oct; 99(1):277-87. PubMed ID: 16987250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.
    Arranz MJ; Munro J; Owen MJ; Spurlock G; Sham PC; Zhao J; Kirov G; Collier DA; Kerwin RW
    Mol Psychiatry; 1998 Jan; 3(1):61-6. PubMed ID: 9491814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
    Arranz MJ; Collier DA; Munro J; Sham P; Kirov G; Sodhi M; Roberts G; Price J; Kerwin RW
    Neurosci Lett; 1996 Oct; 217(2-3):177-8. PubMed ID: 8916101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia.
    Souza RP; de Luca V; Meltzer HY; Lieberman JA; Kennedy JL
    Pharmacogenet Genomics; 2010 Apr; 20(4):274-6. PubMed ID: 20168265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.
    Yu YW; Tsai SJ; Yang KH; Lin CH; Chen MC; Hong CJ
    Neuropsychobiology; 2001; 43(2):79-82. PubMed ID: 11174050
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic variation of 5-HT2A receptor and response to clozapine.
    Masellis M; Paterson AD; Badri F; Lieberman JA; Meltzer HY; Cavazzoni P; Kennedy JL
    Lancet; 1995 Oct; 346(8982):1108. PubMed ID: 7564821
    [No Abstract]   [Full Text] [Related]  

  • 53. Serotonin-6 receptor variant (C267T) and clinical response to clozapine.
    Yu YW; Tsai SJ; Lin CH; Hsu CP; Yang KH; Hong CJ
    Neuroreport; 1999 Apr; 10(6):1231-3. PubMed ID: 10363930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.
    Molero P; Ortuño F; Zalacain M; Patiño-García A
    Pharmacogenomics J; 2007 Dec; 7(6):418-26. PubMed ID: 17363961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.
    Huang E; Maciukiewicz M; Zai CC; Tiwari AK; Li J; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Kennedy JL
    Pharmacogenomics; 2016; 17(2):103-9. PubMed ID: 26666695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment.
    Bosia M; Zanoletti A; Spangaro M; Buonocore M; Bechi M; Cocchi F; Pirovano A; Lorenzi C; Bramanti P; Smeraldi E; Cavallaro R
    Psychiatry Res; 2014 Jun; 217(1-2):9-14. PubMed ID: 24656901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COMT158 polymorphism and hostility.
    Volavka J; Kennedy JL; Ni X; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Lieberman JA
    Am J Med Genet B Neuropsychiatr Genet; 2004 May; 127B(1):28-9. PubMed ID: 15108175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia.
    Blasi G; Napolitano F; Ursini G; Di Giorgio A; Caforio G; Taurisano P; Fazio L; Gelao B; Attrotto MT; Colagiorgio L; Todarello G; Piva F; Papazacharias A; Masellis R; Mancini M; Porcelli A; Romano R; Rampino A; Quarto T; Giulietti M; Lipska BK; Kleinman JE; Popolizio T; Weinberger DR; Usiello A; Bertolino A
    Am J Psychiatry; 2013 Aug; 170(8):868-76. PubMed ID: 23598903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
    Ewald HL; Mors NP; Rosenberg R
    Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful Readministration of Clozapine in a Patient With a History of Clozapine-Induced Elevation of Creatine Phosphokinase.
    Takahashi Y; Ogihara T; Sasayama D; Washizuka S
    Prim Care Companion CNS Disord; 2017 Aug; 19(4):. PubMed ID: 28817763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.